West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
West Pharmaceutical Services, Inc. (WST) Net margin
West Pharmaceutical Services, Inc.'s net margin over the twelve months to 30 June 2026 was 17.0%, up 0.9 percentage points from fiscal 2025 (16.1%). Over the past ten years it has ranged from 6.83% (fiscal 2015) to 23.4% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 16.1% | (0.97) |
| FY2024 | 17.0% | (3.09) |
| FY2023 | 20.1% | (0.18) |
| FY2022 | 20.3% | (3.07) |
| FY2021 | 23.4% | 7.24 |
| FY2020 | 16.1% | 2.99 |
| FY2019 | 13.1% | 1.09 |
| FY2018 | 12.1% | 2.63 |
| FY2017 | 9.42% | (0.10) |
| FY2016 | 9.52% | 2.69 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 17.7% | 1.22 |
| Mar 2026 | 16.4% | 0.02 |
| Dec 2025 | 16.4% | (0.99) |
| Sep 2025 | 17.4% | 0.20 |
| 42 more quarters | Free account |
Against its own ten years
Low 6.83%
High 23.4%
Ten-year median
16.1%
Current reading's percentile
55
Net margin against peers
| Company | Net margin |
|---|---|
| RMD ResMed Inc. compare | 26.9% |
| SOLV Solventum Corporation compare | 17.3% |
| WST West Pharmaceutical Services, Inc. | 17.0% |
| COO The Cooper Companies, Inc. compare | 13.5% |
| ALC Alcon compare | 5.92% |
| RGEN Repligen Corporation compare | 5.29% |
| BDX Becton, Dickinson and Company compare | 4.20% |
| MDLN Medline Inc. compare | 2.37% |
| BAX Baxter International Inc. compare | −9.27% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement